Mobile Cardiac Outpatient Telemetry

Size: px
Start display at page:

Download "Mobile Cardiac Outpatient Telemetry"

Transcription

1 MEDICAL POLICY Mobile Cardiac Outpatient Telemetry BCBSA Ref. Policy: Effective Date: Aug. 1, 2017 Last Revised: July 11, 2017 Replaces: N/A RELATED MEDICAL POLICIES: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA CODING RELATED INFORMATION EVIDENCE REVIEW REFERENCES HISTORY Clicking this icon returns you to the hyperlinks menu above. Introduction Mobile cardiac outpatient telemetry is a small device that is connected to wires that are attached to the chest. It sends information to a distant doctor s office when an uneven heart rhythm is detected. It is considered an alternative to other heart monitors. There is not enough information from studies to be certain that this type of device works as well as other heart monitors in reducing heart problems and death. The use of this device is not yet proven. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered. Policy Coverage Criteria Procedure Outpatient cardiac telemetry (aka, mobile cardiac outpatient telemetry) Investigational Using outpatient cardiac telemetry (also known as mobile cardiac outpatient telemetry) as a diagnostic alternative to ambulatory event monitors is considered investigational.

2 Coding Code Description CPT External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real-time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS). Related Information The available evidence suggests that long-term monitoring for atrial fibrillation after cryptogenic stroke or post cardiac ablation is associated with improved outcomes, but the specific type of monitoring associated with the best outcomes is not well-defined. Trials that have demonstrated improved outcomes have used either event monitors or implantable monitors. In addition, there are individual patient considerations that may make one type of monitor preferable over another. Table 1. Mobile Cardiac Outpatient Telemetry Device Class Description Sample Devices Mobile cardiac outpatient telemetry Continuously recording or CardioNetMCOT (BioTelemetry, autotriggered memory loop devices Malvern, PA) that transmit data to a central LifeStar Mobile Cardiac Page 2 of 7

3 Device Class Description Sample Devices recording station with real-time Telemetry (LifeWatch Services, monitoring and analysis Switzerland) SEEQ Mobile Cardiac Telemetry (Medtronic, Minneapolis, MN) Evidence Review Summary of Evidence For individuals with signs and/or symptoms suggestive of arrhythmia who receive outpatient cardiac telemetry, the evidence includes 1 RCT and nonrandomized studies evaluating rates of arrhythmia detection. Relevant outcomes are overall survival and morbid events. The available evidence has suggested that outpatient cardiac telemetry is at least as good at detecting arrhythmias as ambulatory event monitoring. However, studies have not evaluated whether the real-time monitoring feature of outpatient cardiac telemetry leads to reduced cardiac events and mortality. The evidence is insufficient to determine the effects of the technology on health outcomes. Therefore the use of these devices is considered investigational. Mobile Cardiac Outpatient Telemetry This policy addresses whether the addition of real-time monitoring (mobile cardiac outpatient telemetry, or MCOT) to ambulatory cardiac monitoring is associated with improved outcomes. Two factors must be addressed in evaluating MCOT: (1) the inherent detection capability of the monitoring devices and (2) whether the real-time transmission and interpretation of data confers an incremental health benefit. The proposed addition of real-time monitoring suggests that there may be a subset of individuals who require immediate intervention when an arrhythmia is detected. It is not clear which patients comprise that subset, or whether identification of those patients in the outpatient setting leads to improved outcomes such as reduced risk of sudden cardiac death. Additional studies must be done to assess the benefits of real-time transmission of data and not just arrhythmia detection rates. One RCT was identified that compared MCOT with standard event monitors. 2 This study enrolled patients at 17 centers and involved 305 patients randomly assigned to the LOOP recorder or MCOT and were monitored for up to 30 days. Those enrolled were patients for whom the investigators had a strong suspicion of an arrhythmic cause of symptoms which included Page 3 of 7

4 syncope, presyncope, or severe palpitations occurring less frequently than once per 24 hours. The enrollees also all had a nondiagnostic 24-hour Holter or telemetry monitor within the prior 45 days. Test results were read in a blinded fashion by an electrophysiologist. Most patients in the control group had a patient-triggered event monitor. Only a subset of patients (n=50) had autotrigger devices, thus precluding comparison of MCOT and autotrigger devices. A diagnostic end point (confirmation/exclusion of an arrhythmic cause of symptoms) was found in 88% of MCOT patients and in 75% of LOOP patients (p=0.008). The difference in rates was primarily due to detection of asymptomatic arrhythmias (not associated with simultaneous symptoms) in the MCOT group. These symptoms consisted of rapid AF and/or flutter (15 patients vs 1 patient) and ventricular tachycardia defined as more than 3 beats and rate greater than 100 (14 patients vs 2 patients). These differences were thought to be clinically significant rhythm disturbances and the likely causes of the patients symptoms. The authors did not comment on the clinical impact (changes in management) of these findings in patients for whom the rhythm disturbance was not linked to symptoms. In this study, median time to diagnosis in the total study population was 7 days in the MCOT group and 9 days in the LOOP group. Kadish et al evaluated the frequency with which events transmitted by MCOT represented emergent arrhythmias, thereby indirectly assessing the clinical utility of real-time outpatient monitoring. 3 A total of 26,438 patients who had undergone MCOT during a 9-month period were retrospectively examined. Of these patients, 21% (5,459) had an arrhythmic event requiring physician notification, and 1% (260) had an event that could be considered potentially emergent. These potentially emergent events included 120 patients with wide-complex tachycardia, 100 patients with sinus pauses 6 seconds or longer, and 42 with sustained bradycardia at less than 30 beats per minute. A number of uncontrolled case series have reported on arrhythmia detection rates of MCOT. 4-7 One such published study described the outcomes of a consecutive case series of 100 patients. 4 Patients with a variety of symptoms were included, most commonly palpitations (47%), dizziness (24%), or syncope (19%), as well as those being evaluated for efficacy of drug treatment (25%). Clinically significant arrhythmias were detected in 51% of patients, but half of these patients were asymptomatic. The authors commented that the automatic detection resulted in an increased diagnostic yield, but there was no discussion of its unique feature (ie, the real-time analysis, transmission, and notification of arrhythmia). Studies have evaluated the use of MCOT in detecting AF. In the largest study evaluating the diagnostic yield of MCOT for AF, Favilla et al reported results of a retrospective cohort of 227 patients with cryptogenic stroke or TIA who underwent 28 days of monitoring with mobile cardiac outpatient telemetry. 8 AF was detected in 14% (31/227) of patients, of whom 3 reported Page 4 of 7

5 symptoms at the time of AF. Oral anticoagulation was initiated in 26 (84%) patients diagnosed with AF. Of the remaining 5 (16%) who were not anticoagulated, 1 had a prior history of gastrointestinal bleeding, 3 were unwilling to accept the risk of bleeding, and 1 failed to followup. In an uncontrolled case series, Tayal et al retrospectively analyzed patients with cryptogenic stroke who had not been diagnosed with AF by standard monitoring. 7 In this study, 13 (23%) of 56 patients with cryptogenic stroke had AF with MCOT. Twenty-seven asymptomatic AF episodes were detected in the 13 patients, and 23 of these were less than 30 seconds in duration. In contrast, Kalani et al reported a diagnostic yield for AF of 4.7% (95% CI, 1.5% to 11.9%) in a series of 85 patients with cryptogenic stroke. 9 In this series, 82.4% of patients had completed transesophageal echocardiography, cardiac magnetic resonance imaging (cmri), or both, with negative results. The authors proposed that the use of advanced cardiac imaging may alter the underlying prevalence of AF in patients labeled as having cryptogenic stroke. In an earlier retrospective cohort study, Miller et al retrospectively analyzed paroxysmal AF detection rates among 156 patients evaluated with MCOT within 6 months of a cryptogenic stroke or TIA. 1 Over a median 21-day period of MCOT monitoring (range, 1-30 days), AF was detected in 17.3% of patients. Mean time to first occurrence of AF was 8.8 days (range, 1-21 days). Section Summary The available evidence suggests that MCOT is likely at least as good at detecting arrhythmias as ambulatory event monitoring. Compared with ambulatory event monitoring, MCOT is associated with the theoretical advantage of real-time monitoring, allowing for emergent intervention for potentially life-threatening arrhythmias. One study reported that 1% of arrhythmic events detected on MCOT over a 9-month period could be considered potentially emergent. However, no studies were identified that addressed whether the use of MCOT is associated with differences in the management of or outcomes after these potentially emergent events. The addition of real-time monitoring to outpatient ambulatory monitoring is considered an enhancement to existing technology. There is insufficient evidence to demonstrate a clinically significant incremental benefit of MCOT. Therefore this service is considered investigational. Page 5 of 7

6 Clinical Input Received From Physician Specialty Societies and Academic Medical Centers Clinical input was obtained from 4 academic medical centers (3 reviews) and 3 physician specialty societies to provide information on mobile cardiac outpatient telemetry (MCOT) and new devices. There was no consensus whether MCOT is medically necessary. Reviewers did not agree whether real-time monitoring provides incremental benefits or improved health outcomes over ambulatory monitoring that is not being reviewed in real time. Medicare National Coverage There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers. References 1. Miller DJ, Khan MA, Schultz LR, et al. Outpatient cardiac telemetry detects a high rate of atrial fibrillation in t. Clin Cardiol. Oct 2014;37(10): PMID Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol. Mar 2007;18(3): PMID Kadish AH, Reiffel JA, Clauser J, et al. Frequency of serious arrhythmias detected with ambulatory cardiac telemetry. Am J Cardiol. May ;105(9): PMID Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol. Apr ;95(7): PMID Olson JA, Fouts AM, Padanilam BJ, et al. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. J Cardiovasc Electrophysiol. May 2007;18(5): PMID Saarel EV, Doratotaj S, Sterba R. Initial experience with novel mobile cardiac outpatient telemetry for children and adolescents with suspected arrhythmia. Congenital heart disease. Jan-Feb 2008;3(1): PMID Tayal AH, Tian M, Kelly KM, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. Nov ;71(21): PMID Favilla CG, Ingala E, Jara J, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke. May 2015;46(5): PMID Kalani R, Bernstein R, Passman R, et al. Low yield of mobile cardiac outpatient telemetry after cryptogenic stroke in patients with extensive cardiac imaging. J Stroke Cerebrovasc Dis. Sep 2015;24(9): PMID Page 6 of 7

7 10. Calkins H, Kuck KH, Cappato R, et al HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol. Mar 2012;33(2): PMID Blue Cross Blue Shield Association. Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry. Medical Policy Reference Manual. Policy , History Date Comments 08/09/16 New policy, add to Cardiology section. Use of MCOT is considered investigational. Policy will be effective 01/01/17. 10/25/16 Effective date revision. Policy will be effective 03/01/17. 02/24/17 Effective date revision. Policy will be effective 03/15/17. 03/15/17 Effective date revision. Policy will be effective 03/17/17. 03/17/17 Effective date revision. Policy will be effective 03/31/17. 03/23/17 Effective date revision. Policy will be effective 03/24/17. Coding update; removed CPT codes 0295T-0298T. Minor formatting update. 08/01/17 Annual review, approved July 11, No changes to policy statement. Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA) Premera All Rights Reserved. Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage. Page 7 of 7

8 Discrimination is Against the Law LifeWise Health Plan of Oregon complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability or sex. LifeWise: Provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: Qualified interpreters Information written in other languages If you need these services, contact the Civil Rights Coordinator. If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator - Complaints and Appeals PO Box 91102, Seattle, WA Toll free , Fax , TTY AppealsDepartmentInquiries@LifeWiseHealth.com You can file a grievance in person or by mail, fax, or . If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue SW, Room 509F, HHH Building Washington, D.C , , (TDD) Complaint forms are available at Getting Help in Other Languages This Notice has Important Information. This notice may have important information about your application or coverage through LifeWise Health Plan of Oregon. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call አማሪኛ (Amharic): ይህ ማስታወቂያ አስፈላጊ መረጃ ይዟል ይህ ማስታወቂያ ስለ ማመልከቻዎ ወይም የ LifeWise Health Plan of Oregon ሽፋን አስፈላጊ መረጃ ሊኖረው ይችላል በዚህ ማስታወቂያ ውስጥ ቁልፍ ቀኖች ሊኖሩ ይችላሉ የጤናን ሽፋንዎን ለመጠበቅና በአከፋፈል እርዳታ ለማግኘት በተውሰኑ የጊዜ ገደቦች እርምጃ መውሰድ ይገባዎት ይሆናል ይህን መረጃ እንዲያገኙ እና ያለምንም ክፍያ በቋንቋዎ እርዳታ እንዲያገኙ መብት አለዎት በስልክ ቁጥር (TTY: ) ይደውሉ (Arabic): العربية يحوي ھذا اإلشعار معلومات ھامة. قد يحوي ھذا اإلشعار معلومات مھمة بخصوص طلبك أو التغطية التي تريد الحصول عليھا من خالل.LifeWise Health Plan of Oregon قد تكون ھناك تواريخ مھمة في ھذا اإلشعار. وقد تحتاج التخاذ إجراء في تواريخ معينة للحفاظ على تغطيتك الصحية أو للمساعدة في دفع التكاليف. يحق لك الحصول على ھذه المعلومات والمساعدة بلغتك دون تكبد أية تكلفة. اتصل ب( (TTY: 中文 (Chinese): 本通知有重要的訊息 本通知可能有關於您透過 LifeWise Health Plan of Oregon 提交的申請或保險的重要訊息 本通知內可能有重要日期 您可能需要在截止日期之前採取行動, 以保留您的健康保險或者費用補貼 您有權利免費以您的母語得到本訊息和幫助 請撥電話 (TTY: ) Oromoo (Cushite): Beeksisni kun odeeffannoo barbaachisaa qaba. Beeksisti kun sagantaa yookan karaa LifeWise Health Plan of Oregon tiin tajaajila keessan ilaalchisee odeeffannoo barbaachisaa qabaachuu danda a. Guyyaawwan murteessaa ta an beeksisa kana keessatti ilaalaa. Tarii kaffaltiidhaan deeggaramuuf yookan tajaajila fayyaa keessaniif guyyaa dhumaa irratti wanti raawwattan jiraachuu danda a. Kaffaltii irraa bilisa haala ta een afaan keessaniin odeeffannoo argachuu fi deeggarsa argachuuf mirga ni qabaattu. Lakkoofsa bilbilaa (TTY: ) tii bilbilaa. Français (French): Cet avis a d'importantes informations. Cet avis peut avoir d'importantes informations sur votre demande ou la couverture par l'intermédiaire de LifeWise Health Plan of Oregon. Le présent avis peut contenir des dates clés. Vous devrez peut-être prendre des mesures par certains délais pour maintenir votre couverture de santé ou d'aide avec les coûts. Vous avez le droit d'obtenir cette information et de l aide dans votre langue à aucun coût. Appelez le Kreyòl ayisyen (Creole): Avi sila a gen Enfòmasyon Enpòtan ladann. Avi sila a kapab genyen enfòmasyon enpòtan konsènan aplikasyon w lan oswa konsènan kouvèti asirans lan atravè LifeWise Health Plan of Oregon. Kapab genyen dat ki enpòtan nan avi sila a. Ou ka gen pou pran kèk aksyon avan sèten dat limit pou ka kenbe kouvèti asirans sante w la oswa pou yo ka ede w avèk depans yo. Se dwa w pou resevwa enfòmasyon sa a ak asistans nan lang ou pale a, san ou pa gen pou peye pou sa. Rele nan Deutsche (German): Diese Benachrichtigung enthält wichtige Informationen. Diese Benachrichtigung enthält unter Umständen wichtige Informationen bezüglich Ihres Antrags auf Krankenversicherungsschutz durch LifeWise Health Plan of Oregon. Suchen Sie nach eventuellen wichtigen Terminen in dieser Benachrichtigung. Sie könnten bis zu bestimmten Stichtagen handeln müssen, um Ihren Krankenversicherungsschutz oder Hilfe mit den Kosten zu behalten. Sie haben das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Rufen Sie an unter Hmoob (Hmong): Tsab ntawv tshaj xo no muaj cov ntshiab lus tseem ceeb. Tej zaum tsab ntawv tshaj xo no muaj cov ntsiab lus tseem ceeb txog koj daim ntawv thov kev pab los yog koj qhov kev pab cuam los ntawm LifeWise Health Plan of Oregon. Tej zaum muaj cov hnub tseem ceeb uas sau rau hauv daim ntawv no. Tej zaum koj kuj yuav tau ua qee yam uas peb kom koj ua tsis pub dhau cov caij nyoog uas teev tseg rau hauv daim ntawv no mas koj thiaj yuav tau txais kev pab cuam kho mob los yog kev pab them tej nqi kho mob ntawd. Koj muaj cai kom lawv muab cov ntshiab lus no uas tau muab sau ua koj hom lus pub dawb rau koj. Hu rau Iloko (Ilocano): Daytoy a Pakdaar ket naglaon iti Napateg nga Impormasion. Daytoy a pakdaar mabalin nga adda ket naglaon iti napateg nga impormasion maipanggep iti apliksayonyo wenno coverage babaen iti LifeWise Health Plan of Oregon. Daytoy ket mabalin dagiti importante a petsa iti daytoy a pakdaar. Mabalin nga adda rumbeng nga aramidenyo nga addang sakbay dagiti partikular a naituding nga aldaw tapno mapagtalinaedyo ti coverage ti salun-atyo wenno tulong kadagiti gastos. Adda karbenganyo a mangala iti daytoy nga impormasion ken tulong iti bukodyo a pagsasao nga awan ti bayadanyo. Tumawag iti numero nga Italiano (Italian): Questo avviso contiene informazioni importanti. Questo avviso può contenere informazioni importanti sulla tua domanda o copertura attraverso LifeWise Health Plan of Oregon. Potrebbero esserci date chiave in questo avviso. Potrebbe essere necessario un tuo intervento entro una scadenza determinata per consentirti di mantenere la tua copertura o sovvenzione. Hai il diritto di ottenere queste informazioni e assistenza nella tua lingua gratuitamente. Chiama ( )

9 日本語 (Japanese): この通知には重要な情報が含まれています この通知には LifeWise Health Plan of Oregon の申請または補償範囲に関する重要な情報が含まれている場合があります この通知に記載されている可能性がある重要な日付をご確認ください 健康保険や有料サポートを維持するには 特定の期日までに行動を取らなければならない場合があります ご希望の言語による情報とサポートが無料で提供されます (TTY: ) までお電話ください 한국어 (Korean): 본통지서에는중요한정보가들어있습니다. 즉이통지서는귀하의신청에관하여그리고 LifeWise Health Plan of Oregon 를통한커버리지에관한정보를포함하고있을수있습니다. 본통지서에는핵심이되는날짜들이있을수있습니다. 귀하는귀하의건강커버리지를계속유지하거나비용을절감하기위해서일정한마감일까지조치를취해야할필요가있을수있습니다. 귀하는이러한정보와도움을귀하의언어로비용부담없이얻을수있는권리가있습니다 (TTY: ) 로전화하십시오. ລາວ (Lao): ແຈ ງການນ ມ ຂ ມ ນສ າຄ ນ. ແຈ ງການນ ອາດຈະມ ຂ ມ ນສ າຄ ນກ ຽວກ ບຄ າຮ ອງສະ ໝ ກ ຫ ຄວາມຄ ມຄອງປະກ ນໄພຂອງທ ານຜ ານ LifeWise Health Plan of Oregon. ອາດຈະມ ວ ນທ ສ າຄ ນໃນແຈ ງການນ. ທ ານອາດຈະຈ າເປ ນຕ ອງດ າເນ ນ ການຕາມກ ານ ດເວລາສະເພາະເພ ອຮ ກສາຄວາມຄ ມຄອງປະກ ນສ ຂະພາບ ຫ ຄວາ ມຊ ວຍເຫ ອເລ ອງຄ າໃຊ ຈ າຍຂອງທ ານໄວ. ທ ານມ ສ ດໄດ ຮ ບຂ ມ ນນ ແລະ ຄວາມ ຊ ວຍເຫ ອເປ ນພາສາຂອງທ ານໂດຍບ ເສຍຄ າ. ໃຫ ໂທຫາ ភ ស ខមរ (Khmer): សចកត ជ នដ ណ ង ន ម នព ត ម នយ ងស ខ ន សចកត ជ នដ ណ ង ន រប ហល ជ ម នព ត ម នយ ងស ខ ន អ ព ទរមង បបបទ ឬក ររ ប រងរបស អនកត មរយ LifeWise Health Plan of Oregon រប ហលជ ម ន ក លបរ ចឆទស ខ ន ន កន ង សចកត ជ នដ ណ ង ន អនករប ហលជ រត វក រប ញច ញសមតថភ ព ដល ក ណត ថង ជ ក ចប ស ន ន ដ មប ន ងរកស ទ កក រធ ន រ ប រងស ខភ ពរបស អនក ឬរប ក ជ ន យ ចញ ថល អនកម នស ទធ ទទ លព ត ម ន ន ន ងជ ន យ ន កន ងភ ស របស អនក ដ យម នអសល យ ឡ យ ស មទ រស ពទ (TTY: ) ਪ ਜ ਬ (Punjabi): ਇਸ ਨ ਟਸ ਵਚ ਖ ਸ ਜ ਣਕ ਰ ਹ. ਇਸ ਨ ਟਸ ਵਚ LifeWise Health Plan of Oregon ਵਲ ਤ ਹ ਡ ਕਵਰ ਜ ਅਤ ਅਰਜ ਬ ਰ ਮਹ ਤਵਪ ਰਨ ਜ ਣਕ ਰ ਹ ਸਕਦ ਹ. ਇਸ ਨ ਜਸ ਜਵਚ ਖ ਸ ਤ ਰ ਖ ਹ ਸਕਦ ਆ ਹਨ. ਜ ਕਰ ਤ ਸ ਜਸਹਤ ਕਵਰ ਜ ਰ ਖਣ ਹ ਵ ਜ ਓਸ ਦ ਲ ਗਤ ਜ ਵ ਚ ਮਦਦ ਦ ਇਛ ਕ ਹ ਤ ਤ ਹ ਨ ਅ ਤਮ ਤ ਰ ਖ਼ ਤ ਪ ਹਲ ਕ ਝ ਖ ਸ ਕਦਮ ਚ ਕਣ ਦ ਲ ੜ ਹ ਸਕਦ ਹ,ਤ ਹ ਨ ਮ ਫ਼ਤ ਵ ਚ ਤ ਆਪਣ ਭ ਸ਼ ਵ ਚ ਜ ਣਕ ਰ ਅਤ ਮਦਦ ਪ ਰ ਪਤ ਕਰਨ ਦ ਅ ਧਕ ਰ ਹ,ਕ ਲ (Farsi): فارسی اين اعالميه حاوی اطالعات مھم ميباشد.اين اعالميه ممکن است حاوی اطالعات مھم درباره فرم تقاضا و يا پوشش بيمه ای شما از طريق LifeWise Health Plan of Oregon باشد. به تاريخ ھای مھم در اين اعالميه توجه نماييد.شما ممکن است برای حقظ پوشش بيمه تان يا کمک در پرداخت ھزينه ھای درمانی تان به تاريخ ھای مشخصی برای انجام کارھای خاصی احتياج داشته باشيد.شما حق اين را داريد که اين اطالعات و کمک را به زبان خود به طور رايگان دريافت نماييد. برای کسب اطالعات با شماره (کاربران TTY تماس باشماره ) تماس برقرار نماييد. Polskie (Polish): To ogłoszenie może zawierać ważne informacje. To ogłoszenie może zawierać ważne informacje odnośnie Państwa wniosku lub zakresu świadczeń poprzez LifeWise Health Plan of Oregon. Prosimy zwrócic uwagę na kluczowe daty, które mogą być zawarte w tym ogłoszeniu aby nie przekroczyć terminów w przypadku utrzymania polisy ubezpieczeniowej lub pomocy związanej z kosztami. Macie Państwo prawo do bezpłatnej informacji we własnym języku. Zadzwońcie pod Português (Portuguese): Este aviso contém informações importantes. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do LifeWise Health Plan of Oregon. Poderão existir datas importantes neste aviso. Talvez seja necessário que você tome providências dentro de determinados prazos para manter sua cobertura de saúde ou ajuda de custos. Você tem o direito de obter esta informação e ajuda em seu idioma e sem custos. Ligue para Română (Romanian): Prezenta notificare conține informații importante. Această notificare poate conține informații importante privind cererea sau acoperirea asigurării dumneavoastre de sănătate prin LifeWise Health Plan of Oregon. Pot exista date cheie în această notificare. Este posibil să fie nevoie să acționați până la anumite termene limită pentru a vă menține acoperirea asigurării de sănătate sau asistența privitoare la costuri. Aveți dreptul de a obține gratuit aceste informații și ajutor în limba dumneavoastră. Sunați la Pусский (Russian): Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через LifeWise Health Plan of Oregon. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону Fa asamoa (Samoan): Atonu ua iai i lenei fa asilasilaga ni fa amatalaga e sili ona taua e tatau ona e malamalama i ai. O lenei fa asilasilaga o se fesoasoani e fa amatala atili i ai i le tulaga o le polokalame, LifeWise Health Plan of Oregon, ua e tau fia maua atu i ai. Fa amolemole, ia e iloilo fa alelei i aso fa apitoa olo o iai i lenei fa asilasilaga taua. Masalo o le a iai ni feau e tatau ona e faia ao le i aulia le aso ua ta ua i lenei fa asilasilaga ina ia e iai pea ma maua fesoasoani mai ai i le polokalame a le Malo olo o e iai i ai. Olo o iai iate oe le aia tatau e maua atu i lenei fa asilasilaga ma lenei fa matalaga i legagana e te malamalama i ai aunoa ma se togiga tupe. Vili atu i le telefoni Español (Spanish): Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de LifeWise Health Plan of Oregon. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al Tagalog (Tagalog): Ang Paunawa na ito ay naglalaman ng mahalagang impormasyon. Ang paunawa na ito ay maaaring naglalaman ng mahalagang impormasyon tungkol sa iyong aplikasyon o pagsakop sa pamamagitan ng LifeWise Health Plan of Oregon. Maaaring may mga mahalagang petsa dito sa paunawa. Maaring mangailangan ka na magsagawa ng hakbang sa ilang mga itinakdang panahon upang mapanatili ang iyong pagsakop sa kalusugan o tulong na walang gastos. May karapatan ka na makakuha ng ganitong impormasyon at tulong sa iyong wika ng walang gastos. Tumawag sa ไทย (Thai): ประกาศน ม ข อม ลส าค ญ ประกาศน อาจม ข อม ลท ส าค ญเก ยวก บการการสม ครหร อขอบเขตประก น ส ขภาพของค ณผ าน LifeWise Health Plan of Oregon และอาจม ก าหนดการในประกาศน ค ณ อาจจะต องด าเน นการภายในก าหนดระยะเวลาท แน นอนเพ อจะร กษาการประก นส ขภาพของค ณหร อการ ช วยเหล อท ม ค าใช จ าย ค ณม ส ทธ ท จะได ร บข อม ลและความช วยเหล อน ในภาษาของค ณโดยไม ม ค าใช จ าย โทร (TTY: ) Український (Ukrainian): Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страхувального покриття через LifeWise Health Plan of Oregon. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дзвоніть за номером телефону Tiếng Việt (Vietnamese): Thông báo này cung cấp thông tin quan trọng. Thông báo này có thông tin quan trọng về đơn xin tham gia hoặc hợp đồng bảo hiểm của quý vị qua chương trình LifeWise Health Plan of Oregon. Xin xem ngày quan trọng trong thông báo này. Quý vị có thể phải thực hiện theo thông báo đúng trong thời hạn để duy trì bảo hiểm sức khỏe hoặc được trợ giúp thêm về chi phí. Quý vị có quyền được biết thông tin này và được trợ giúp bằng ngôn ngữ của mình miễn phí. Xin gọi số

Behavioral Health: Residential/Sub-Acute Detoxification

Behavioral Health: Residential/Sub-Acute Detoxification UTILIZATION MANAGEMENT GUIDELINE 3.01.515 Behavioral Health: Residential/Sub-Acute Detoxification Effective Date: Dec. 1, 2017 Last Revised: Nov. 9, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 3.01.520

More information

2017 Individual Pediatric Dental Plans

2017 Individual Pediatric Dental Plans 2017 Individual Pediatric Dental Plans For Washington residents under age 19 living in select counties Good oral health is good for overall health. That s why Premera Blue Cross has offered dental plans

More information

Preventive Care Tip Sheet

Preventive Care Tip Sheet Preventive Care Tip Sheet Your powerful preventive care benefits With your Premera health plan, you can access excellent preventive care benefits. When you use an in-network provider, ALL preventive care

More information

Using your preventive benefits

Using your preventive benefits Using your preventive benefits Your Premera Blue Cross plan pays in-network preventive services in full. You ll get the most value from these benefits by choosing a doctor in your plan s network. Getting

More information

Using your preventive benefits

Using your preventive benefits Using your preventive benefits Your Premera Blue Cross plan pays in-network preventive services in full You ll get the most value from these benefits by choosing a doctor in your plan s network. Getting

More information

Using Your Preventive Benefits

Using Your Preventive Benefits Using Your Preventive Benefits These are guidelines for routine exams, immunizations and screenings that are covered by your plan as preventive services and are covered in full when received from an in-network

More information

Peripheral Subcutaneous Field Stimulation

Peripheral Subcutaneous Field Stimulation MEDICAL POLICY 7.01.139 Peripheral Subcutaneous Field Stimulation BCBSA Ref. Policy: 7.01.139 Effective Date: July 1, 2017 Last Revised: Jan. 1, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select

More information

Imlygic (talimogene laherparepvec)

Imlygic (talimogene laherparepvec) PHARMACY POLICY 5.01.562 Imlygic (talimogene laherparepvec) Effective Date: Oct. 1, 2017 Last Revised: Sept. 5, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors

More information

Select a hyperlink below to be directed to that section. COVERAGE GUIDELINE CODING RELATED INFORMATION REFERENCES HISTORY

Select a hyperlink below to be directed to that section. COVERAGE GUIDELINE CODING RELATED INFORMATION REFERENCES HISTORY BENEFIT COVERAGE GUIDELINE 10.01.519 Colonoscopy Effective Date: March 1, 2018 Last Revised: Feb. 6, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 12.04.506 Genetic Testing for Lynch Syndrome and Other

More information

Using your preventive benefits

Using your preventive benefits Using your preventive benefits Your Premera Blue Cross Blue Shield Alaska plan pays in-network preventive services in full. You ll get the most value from these benefits by choosing a doctor in your plan

More information

RELATED MEDICAL POLICIES: None. Select a hyperlink below to be directed to that section.

RELATED MEDICAL POLICIES: None. Select a hyperlink below to be directed to that section. MEDICAL POLICY 2.01.73 Actigraphy BCBSA Ref. Policy: 2.01.73 Effective Date: Sept. 1, 2018 Last Revised: Aug. 10, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be directed

More information

Islet Transplantation

Islet Transplantation MEDICAL POLICY 7.03.12 Islet Transplantation BCBSA Ref. Policy: 7.03.12 Effective Date: Oct. 1, 2017 Last Revised: Sept. 21, 2017 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to

More information

Electronic Brachytherapy for Nonmelanoma Skin Cancer

Electronic Brachytherapy for Nonmelanoma Skin Cancer MEDICAL POLICY 8.01.62 Electronic Brachytherapy for Nonmelanoma Skin Cancer BCBSA Ref. Policy: 8.01.62 Effective Date: Sept. 1, 2017 Last Revised: Aug. 22, 2017 Replaces: N/A RELATED MEDICAL POLICIES:

More information

Molecular Testing in the Management of Pulmonary Nodules

Molecular Testing in the Management of Pulmonary Nodules MEDICAL POLICY 12.04.142 Molecular Testing in the Management of Pulmonary Nodules BCBSA Ref. Policy: 2.04.142 Effective Date: Aug. 1, 2017 Last Revised: July 18, 2017 Replaces: N/A RELATED MEDICAL POLICIES:

More information

Bruton s Kinase Inhibitors

Bruton s Kinase Inhibitors PHARMACY POLICY 5.01.590 Bruton s Kinase Inhibitors Effective Date: Nov. 1, 2018 Last Revised: Oct. 9, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.543 General Medical Necessity Criteria for Companion

More information

Computerized Diagnostic Imaging for Complex Maxillofacial Procedures

Computerized Diagnostic Imaging for Complex Maxillofacial Procedures DENTAL BENEFIT COVERAGE GUIDELINE 9.02.503 Computerized Diagnostic Imaging for Complex Maxillofacial Procedures Effective Date: May 1, 2018 Last Revised: April 3, 2018 Replaces: N/A RELATED DENTAL / MEDICAL

More information

RELATED MEDICAL POLICIES/GUIDELINES: None. Select a hyperlink below to be directed to that section.

RELATED MEDICAL POLICIES/GUIDELINES: None. Select a hyperlink below to be directed to that section. UTILIZATION MANAGEMENT GUIDELINE 9.03.507 Fundus Photography Effective Date: June 1, 2018 Last Revised: May 3, 2018 Replaces: N/A RELATED MEDICAL POLICIES/GUIDELINES: None Select a hyperlink below to be

More information

Islet Transplantation

Islet Transplantation MEDICAL POLICY 7.03.12 Islet Transplantation BCBSA Ref. Policy: 7.03.12 Effective Date: Oct. 1, 2017 Last Revised: Sept. 21, 2017 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to

More information

Sphenopalatine Ganglion Block for Headache

Sphenopalatine Ganglion Block for Headache MEDICAL POLICY 7.01.159 Sphenopalatine Ganglion Block for Headache BCBSA Ref. Policy: 7.01.159 Effective Date: Aug. 1, 2017 Last Revised: July 18, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 7.01.125

More information

RELATED MEDICAL POLICIES: Site of Service: Infusion Drugs and Biologic Agents. Select a hyperlink below to be redirected to that section.

RELATED MEDICAL POLICIES: Site of Service: Infusion Drugs and Biologic Agents. Select a hyperlink below to be redirected to that section. MEDICAL POLICY 5.01.571 Soliris (eculizumab) Effective Date: March 1, 2018 Last Revised: Sept. 21, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 11.01.523 Site of Service: Infusion Drugs and Biologic Agents

More information

Applied Behavior Analysis (ABA)

Applied Behavior Analysis (ABA) MEDICAL POLICY 3.01.510 Applied Behavior Analysis (ABA) Effective Date: Nov. 1, 2018 Last Revised: Oct. 26, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be directed to

More information

Review for Coverage in the Absence of a Medical Policy, Pharmacy Policy, or Utilization Management Guideline

Review for Coverage in the Absence of a Medical Policy, Pharmacy Policy, or Utilization Management Guideline BENEFIT COVERAGE GUIDELINE 10.01.520 Review for Coverage in the Absence of a Medical Policy, Pharmacy Policy, or Utilization Management Guideline Effective Date: June 1, 2018 Last Revised: May 3, 2018

More information

Occupational therapy (OT)

Occupational therapy (OT) MEDICAL POLICY 8.03.503 Occupational Therapy Effective Date: June 1, 2018 Last Revised: June 7, 2018 Replaces: 8.03.03 RELATED MEDICAL POLICIES: 8.03.502 Physical Medicine and Rehabilitation Physical Therapy

More information

Sphenopalatine Ganglion Block for Headache

Sphenopalatine Ganglion Block for Headache MEDICAL POLICY 7.01.159 Sphenopalatine Ganglion Block for Headache BCBSA Ref. Policy: 7.01.159 Effective Date: Aug. 1, 2017 Last Revised: July 18, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 7.01.125

More information

Ampyra (Dalfampridine)

Ampyra (Dalfampridine) PHARMACY POLICY 5.01.527 Ampyra (Dalfampridine) Effective Date: April 1, 2018 Last Revised: March 20, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.550 Pharmacotherapy of Arthropathies Select a hyperlink

More information

Percutaneous Electrical Nerve Stimulation and Percutaneous Neuromodulation Therapy

Percutaneous Electrical Nerve Stimulation and Percutaneous Neuromodulation Therapy MEDICAL POLICY 7.01.29 Percutaneous Electrical Nerve Stimulation and Percutaneous Neuromodulation Therapy BCBSA Ref. Policy: 7.01.29 Effective Date: June 1, 2017 Last Revised: May 2, 2017 Replaces: N/A

More information

Opioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification

Opioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification MEDICAL POLICY 3.01.520 Opioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification Effective Date: April 1, 2017 Last Revised: Oct. 24, 2017 Replaces: 3.01.02

More information

Molecular Genetic Testing: Services Reviewed by AIM

Molecular Genetic Testing: Services Reviewed by AIM ADMINISTRATIVE GUIDELINE 10.01.526 Molecular Genetic Testing: Services Reviewed by AIM Effective Date: Jan. 4, 2019 Last Revised: Dec. 13, 2018 REPLACES MEDICAL POLICIES: 2.04.07 Urinary Biomarkers for

More information

Bronchial Thermoplasty

Bronchial Thermoplasty MEDICAL POLICY 7.01.127 Bronchial Thermoplasty BCBSA Ref. Policy: 7.01.127 Effective Date: Aug. 1, 2017 Last Revised: July 25, 2017 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below

More information

Dry Needling of Myofascial Trigger Points

Dry Needling of Myofascial Trigger Points MEDICAL POLICY 2.01.100 Dry Needling of Myofascial Trigger Points BCBSA Ref. Policy: 2.01.100 Effective Date: Jan. 1, 2019 Last Revised: Dec. 13, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select

More information

Criteria for Safe Management of Opioid Therapy

Criteria for Safe Management of Opioid Therapy PHARMACY / MEDICAL POLICY 5.01.583 Criteria for Safe Management of Opioid Therapy Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink

More information

RELATED MEDICAL POLICIES: None. Select a hyperlink below to be directed to that section.

RELATED MEDICAL POLICIES: None. Select a hyperlink below to be directed to that section. MEDICAL POLICY 2.01.73 Actigraphy BCBSA Ref. Policy: 2.01.73 Effective Date: Nov. 1, 2017 Last Revised: Jan. 1, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be directed

More information

Hearing Aids (Excludes Implantable Devices)

Hearing Aids (Excludes Implantable Devices) BENEFIT COVERAGE GUIDELINE 1.01.528 Hearing Aids (Excludes Implantable Devices) Effective Date: Feb. 1, 2018 Last Revised: Jan. 9, 2018 Replaces: N/A RELATED POLICIES/GUIDELINES: 7.01.05 Cochlear Implant

More information

Peroral Endoscopic Myotomy for Treatment of Esophageal Achalasia

Peroral Endoscopic Myotomy for Treatment of Esophageal Achalasia MEDICAL POLICY 2.01.91 Peroral Endoscopic Myotomy for Treatment of Esophageal Achalasia BCBSA Ref. Policy: 2.01.91 Effective Date: Feb. 1, 2018 RELATED MEDICAL POLICIES: Last Revised: Jan. 9, 2018 2.01.38

More information

Microsoft preventive drug list

Microsoft preventive drug list Microsoft preventive drug list HEALTH SAVINGS PLAN TIP SHEET Prescription drugs The following drugs are considered preventive care and are covered at 100 percent by the plan without being subject to the

More information

Applied Behavior Analysis (ABA)

Applied Behavior Analysis (ABA) MEDICAL POLICY 3.01.510 Applied Behavior Analysis (ABA) Effective Date: Nov. 1, 2018 Last Revised: Oct. 26, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be directed to

More information

Opioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification

Opioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification MEDICAL POLICY 3.01.520 Opioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification Effective Date: April 1, 2017 Last Revised: Oct. 24, 2017 Replaces: 3.01.02

More information

Alcohol Injections for Treatment of Peripheral Neuromas

Alcohol Injections for Treatment of Peripheral Neuromas MEDICAL POLICY 2.01.97 Alcohol Injections for Treatment of Peripheral Neuromas BCBSA Ref. Policy: 2.01.97 Effective Date: Nov. 2, 2018 Last Revised: July 10, 2018 Replaces: N/A RELATED MEDICAL POLICIES:

More information

Cellular Immunotherapy for Prostate Cancer

Cellular Immunotherapy for Prostate Cancer MEDICAL POLICY 8.01.53 Cellular Immunotherapy for Prostate Cancer BCBSA Ref. Policy: 8.01.53 Effective Date: Oct. 1, 2018 Last Revised: Sept. 20, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 8.01.01 Adoptive

More information

Mastectomy for Gynecomastia

Mastectomy for Gynecomastia MEDICAL POLICY 7.01.521 Mastectomy for Gynecomastia BCBSA Ref. Policy: 7.01.13 Effective Date May. 1, 2017 Last Revised: April 11, 2017 Replaces: 7.01.13 RELATED MEDICAL POLICIES: 10.01.514 Cosmetic and

More information

DNA-Based Testing for Adolescent Idiopathic Scoliosis

DNA-Based Testing for Adolescent Idiopathic Scoliosis MEDICAL POLICY 12.04.74 DNA-Based Testing for Adolescent Idiopathic Scoliosis BCBSA Ref. Policy: 2.04.74 Effective Date: May 1, 2018 Last Revised: April 3, 2018 Replaces: 2.04.74 RELATED MEDICAL POLICIES:

More information

Dry Needling of Myofascial Trigger Points

Dry Needling of Myofascial Trigger Points MEDICAL POLICY 2.01.100 Dry Needling of Myofascial Trigger Points BCBSA Ref. Policy: 2.01.100 Effective Date: Jan. 1, 2019 Last Revised: Dec. 13, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select

More information

Palynziq (pegvaliase-pqpz)

Palynziq (pegvaliase-pqpz) MEDICAL POLICY 5.01.585 Palynziq (pegvaliase-pqpz) Effective Date: Aug. 1, 2018 Last Revised: Sept. 21, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be directed to that

More information

Mastectomy for Gynecomastia

Mastectomy for Gynecomastia MEDICAL POLICY 7.01.521 Mastectomy for Gynecomastia BCBSA Ref. Policy: 7.01.13 Effective Date May 1, 2018 Last Revised: April 3, 2018 Replaces: 7.01.13 RELATED MEDICAL POLICIES: 10.01.514 Cosmetic and

More information

Occipital Nerve Stimulation

Occipital Nerve Stimulation MEDICAL POLICY 7.01.125 Occipital Nerve Stimulation BCBSA Ref. Policy: 7.01.125 Effective Date: July 1, 2017 Last Revised: June 6, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 1.01.507 Electrical Stimulation

More information

Gastric Electrical Stimulation

Gastric Electrical Stimulation MEDICAL POLICY 7.01.522 Gastric Electrical Stimulation BCBSA Ref. Policy: 7.01.73 Effective Date: May 1, 2017 Last Revised: Aug. 25, 2017 Replaces: 7.01.73 RELATED MEDICAL POLICIES: 1.01.507 Electrical

More information

Outpatient Pulmonary Rehabilitation

Outpatient Pulmonary Rehabilitation MEDICAL POLICY 8.03.05 Outpatient Pulmonary Rehabilitation BCBSA Ref. Policy: 8.03.05 Effective Date: Nov. 1, 2017 Last Revised: Oct. 19, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 7.03.509 Solid Organ

More information

Multigene Expression Assay for Predicting Recurrence in Colon Cancer

Multigene Expression Assay for Predicting Recurrence in Colon Cancer MEDICAL POLICY 12.04.61 Multigene Expression Assay for Predicting Recurrence in Colon Cancer BCBSA Ref. Policy: 2.04.61 Effective Date: Oct. 1, 2018 Last Revised: Sept. 20, 2018 Replaces: N/A RELATED MEDICAL

More information

Ultrasonographic Measurement of Carotid Intima-Medial Thickness as an Assessment of Subclinical Atherosclerosis

Ultrasonographic Measurement of Carotid Intima-Medial Thickness as an Assessment of Subclinical Atherosclerosis MEDICAL POLICY 2.02.16 Ultrasonographic Measurement of Carotid Intima-Medial Thickness as an Assessment of Subclinical Atherosclerosis BCBSA Ref. Policy: 2.02.16 Effective Date: Aug. 1, 2018 Last Revised:

More information

Hematopoietic Cell Transplantation for Waldenström Macroglobulinemia

Hematopoietic Cell Transplantation for Waldenström Macroglobulinemia MEDICAL POLICY 8.01.531 Hematopoietic Cell Transplantation for Waldenström Macroglobulinemia BCBSA Ref. Policy: 8.01.54 Effective Date: April 1, 2019 Last Revised: March 5, 2019 Replaces: 8.01.54 RELATED

More information

Occipital Nerve Stimulation

Occipital Nerve Stimulation MEDICAL POLICY 7.01.125 Occipital Nerve Stimulation BCBSA Ref. Policy: 7.01.125 Effective Date: July 1, 2017 Last Revised: June 6, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 1.01.507 Electrical Stimulation

More information

Endovascular Therapies for Extracranial Vertebral Artery Disease

Endovascular Therapies for Extracranial Vertebral Artery Disease MEDICAL POLICY 7.01.148 Endovascular Therapies for Extracranial Vertebral Artery Disease BCBSA Ref. Policy: 7.01.148 Effective Date: Aug. 1, 2018 Last Revised: July 25, 2018 Replaces: N/A RELATED MEDICAL

More information

Last Revised: Dec. 6, Recombinant and Autologous Platelet-Derived Growth Factors as a Replaces: N/A

Last Revised: Dec. 6, Recombinant and Autologous Platelet-Derived Growth Factors as a Replaces: N/A MEDICAL POLICY 2.01.26 Prolotherapy BCBSA Ref. Policy: 2.01.26 Effective Date: Jan. 1, 2018 RELATED MEDICAL POLICIES: Last Revised: Dec. 6, 2017 2.01.16 Recombinant and Autologous Platelet-Derived Growth

More information

Outpatient Pulmonary Rehabilitation

Outpatient Pulmonary Rehabilitation MEDICAL POLICY 8.03.05 Outpatient Pulmonary Rehabilitation BCBSA Ref. Policy: 8.03.05 Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 7.03.509 Solid Organ

More information

Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux Disease

Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux Disease MEDICAL POLICY 7.01.137 Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux Disease BCBSA Ref. Policy: 7.01.137 Effective Date: Jan. 1, 2018 Last Revised: Dec. 6, 2017 Replaces:

More information

Venclexta (venetoclax) BCL-2 Inhibitor

Venclexta (venetoclax) BCL-2 Inhibitor PHARMACY POLICY 5.01.568 Venclexta (venetoclax) BCL-2 Inhibitor Effective Date: June 1, 2018 Last Revised: May 3, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.534 Multiple Receptor Tyrosine Kinase

More information

ALK Tyrosine Kinase Inhibitors

ALK Tyrosine Kinase Inhibitors PHARMACY POLICY 5.01.538 ALK Tyrosine Kinase Inhibitors Effective Date: July 1, 2018 Last Revised: June 22, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be directed to

More information

Multimarker Serum Testing Related to Ovarian Cancer

Multimarker Serum Testing Related to Ovarian Cancer MEDICAL POLICY 2.04.62 Multimarker Serum Testing Related to Ovarian Cancer BCBSA Ref. Policy: 2.04.62 Effective Date: Feb. 1, 2018 Last Revised: Jan. 30, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 2.04.125

More information

DNA-Based Testing for Adolescent Idiopathic Scoliosis

DNA-Based Testing for Adolescent Idiopathic Scoliosis MEDICAL POLICY 12.04.74 DNA-Based Testing for Adolescent Idiopathic Scoliosis BCBSA Ref. Policy: 2.04.74 Effective Date: April 1, 2017 Last Revised: Sept. 22, 2017 Replaces: 2.04.74 RELATED MEDICAL POLICIES:

More information

Premera DentalBlueTM. For Washington groups with 51+ employees. Dental Preference Dental Optima Dental Copay Select Dental Essentials

Premera DentalBlueTM. For Washington groups with 51+ employees. Dental Preference Dental Optima Dental Copay Select Dental Essentials Dental Preference Dental Optima Dental Copay Select Dental Essentials Dental Preventive Premera DentalBlueTM For Washington groups with 51+ employees January 2016 Choice. Quality. Your Dental Plan. Premera

More information

Axial Lumbosacral Interbody Fusion

Axial Lumbosacral Interbody Fusion MEDICAL POLICY 7.01.130 Axial Lumbosacral Interbody Fusion BCBSA Ref. Policy: 7.01.130 Effective Date: July 1, 2018 Last Revised: June 22, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 7.01.107 Interspinous

More information

Cardiac Rehabilitation in the Outpatient Setting

Cardiac Rehabilitation in the Outpatient Setting MEDICAL POLICY 8.03.08 Cardiac Rehabilitation in the Outpatient Setting BCBSA Ref. Policy: 8.03.08 Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None

More information

Individual Adult Dental Copay Plan

Individual Adult Dental Copay Plan Individual Adult Dental Copay Plan Preferred Providers Covered Services and Copay Schedule Below is a complete list of services and copays that apply when you use an in-network LifeWise Health Plan of

More information

Single Photon Emission Computed Tomography (SPECT) for Non-cardiac Indications

Single Photon Emission Computed Tomography (SPECT) for Non-cardiac Indications MEDICAL POLICY 6.01.502 Single Photon Emission Computed Tomography (SPECT) for Non-cardiac Indications Effective Date: June 1, 2017 Last Revised: May 23, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 6.01.54

More information

Exondys 51 (eteplirsen)

Exondys 51 (eteplirsen) MEDICAL POLICY 5.01.570 Exondys 51 (eteplirsen) Effective Date: June 1, 2018 Last Revised: June 1, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 11.01.523 Site of Service: Infusion Drugs and Biologic Agents

More information

Exondys 51 (eteplirsen)

Exondys 51 (eteplirsen) MEDICAL POLICY 5.01.570 Exondys 51 (eteplirsen) Effective Date: June 1, 2018* Last Revised: Feb. 13, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None *To view the current policy, click here. Select a

More information

RELATED MEDICAL POLICIES: N/A. Select a hyperlink below to be directed to that section.

RELATED MEDICAL POLICIES: N/A. Select a hyperlink below to be directed to that section. BENEFIT COVERAGE GUIDELINE 10.01.523 Preventive Care Effective Date: Feb. 1, 2018 Last Revised: March 28, 2018 Replaces: N/A RELATED MEDICAL POLICIES: N/A Select a hyperlink below to be directed to that

More information

ALK Tyrosine Kinase Inhibitors

ALK Tyrosine Kinase Inhibitors PHARMACY POLICY 5.01.538 ALK Tyrosine Kinase Inhibitors Effective Date: July 1, 2018 Last Revised: June 22, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be directed to

More information

Myocardial Sympathetic Innervation Imaging in Patients with Heart Failure

Myocardial Sympathetic Innervation Imaging in Patients with Heart Failure MEDICAL POLICY 6.01.56 Myocardial Sympathetic Innervation Imaging in Patients with Heart Failure BCBSA Ref. Policy: 6.01.56 Effective Date: Dec. 1, 2018 Last Revised: Jan. 15, 2019 Replaces: N/A RELATED

More information

CGRP Inhibitors for Migraine Prophylaxis

CGRP Inhibitors for Migraine Prophylaxis PHARMACY POLICY 5.01.584 CGRP Inhibitors for Migraine Prophylaxis Effective Date: June 1, 2018 Last Revised: May 17, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.503 Migraine and Cluster Headache

More information

Cellular Immunotherapy for Prostate Cancer

Cellular Immunotherapy for Prostate Cancer MEDICAL POLICY 8.01.53 Cellular Immunotherapy for Prostate Cancer BCBSA Ref. Policy: 8.01.53 Effective Date: Sept. 1, 2017 Last Revised: Aug. 22, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 8.01.01 Adoptive

More information

Single Photon Emission Computed Tomography (SPECT) for Non-cardiac Indications

Single Photon Emission Computed Tomography (SPECT) for Non-cardiac Indications MEDICAL POLICY 6.01.502 Single Photon Emission Computed Tomography (SPECT) for Non-cardiac Indications Effective Date: June 1, 2017 Last Revised: May 23, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 6.01.54

More information

Last Revised: Dec. 6, Recombinant and Autologous Platelet-Derived Growth Factors as a Replaces: N/A

Last Revised: Dec. 6, Recombinant and Autologous Platelet-Derived Growth Factors as a Replaces: N/A MEDICAL POLICY 2.01.26 Prolotherapy BCBSA Ref. Policy: 2.01.26 Effective Date: Jan. 1, 2018 RELATED MEDICAL POLICIES: Last Revised: Dec. 6, 2017 2.01.16 Recombinant and Autologous Platelet-Derived Growth

More information

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases MEDICAL POLICY 2.04.123 Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases BCBSA Ref. Policy: 2.04.123 Effective Date: Sept. 1, 2017 Last Revised: Aug.

More information

Axial Lumbosacral Interbody Fusion

Axial Lumbosacral Interbody Fusion MEDICAL POLICY 7.01.130 Axial Lumbosacral Interbody Fusion BCBSA Ref. Policy: 7.01.130 Effective Date: July 1, 2018 Last Revised: June 22, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 7.01.107 Interspinous

More information

RELATED MEDICAL POLICIES: None. Select a hyperlink below to be directed to that section.

RELATED MEDICAL POLICIES: None. Select a hyperlink below to be directed to that section. MEDICAL POLICY 7.01.128 Bronchial Valves BCBSA Ref. Policy: 7.01.128 Effective Date: Aug. 1, 2017 Last Revised: July 25, 2017 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink below to be

More information

Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions

Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions MEDICAL POLICY 1.01.15 Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions BCBSA Ref. Policy: 1.01.15 Effective Date: Sept. 1, 2018 Last Revised: Aug. 10, 2018 Replaces:

More information

Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers MEDICAL POLICY 2.04.76 Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers BCBSA Ref. Policy: 2.04.76 Effective Date: March 1, 2018 Last Revised: Feb. 6, 2018 Replaces:

More information

Hetlioz (tasimelteon)

Hetlioz (tasimelteon) PHARMACY POLICY 5.01.552 Hetlioz (tasimelteon) Effective Date: Dec. 1, 2017 Last Revised: Nov. 21, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.605 Medical Necessity Criteria for Pharmacy Edits Select

More information

Cranial Electrotherapy Stimulation and Auricular Electrostimulation

Cranial Electrotherapy Stimulation and Auricular Electrostimulation MEDICAL POLICY 8.01.58 Cranial Electrotherapy Stimulation and Auricular Electrostimulation BCBSA Ref. Policy: 8.01.58 Effective Date: June 1, 2017 Last Revised: Oct. 17, 2017 Replaces: N/A RELATED MEDICAL

More information

Cranial Electrotherapy Stimulation and Auricular Electrostimulation

Cranial Electrotherapy Stimulation and Auricular Electrostimulation MEDICAL POLICY 8.01.58 Cranial Electrotherapy Stimulation and Auricular Electrostimulation BCBSA Ref. Policy: 8.01.58 Effective Date: June 1, 2017 Last Revised: Oct. 17, 2017 Replaces: N/A RELATED MEDICAL

More information

Increlex (mecasermin); Recombinant Human Insulin-Like Growth Factor-1

Increlex (mecasermin); Recombinant Human Insulin-Like Growth Factor-1 PHARMACY POLICY 5.01.519 Increlex (mecasermin); Recombinant Human Insulin-Like Growth Factor-1 Effective Date: Dec. 1, 2017 Last Revised: Nov. 21, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.500

More information

Cooling Devices Used in the Outpatient Setting

Cooling Devices Used in the Outpatient Setting MEDICAL POLICY 1.01.26 Cooling Devices Used in the Outpatient Setting BCBSA Ref. Policy: 1.01.26* Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 1.01.525

More information

Prostate Cancer Targeted Therapies

Prostate Cancer Targeted Therapies PHARMACY POLICY 5.01.544 Prostate Cancer Targeted Therapies Effective Date: July 1, 2018 Last Revised: June 22, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.517 Use of Vascular Endothelial Growth

More information

Panniculectomy and Excision of Redundant Skin

Panniculectomy and Excision of Redundant Skin MEDICAL POLICY 7.01.523 Panniculectomy and Excision of Redundant Skin Effective Date: March 1, 2018 Last Revised: Feb. 13, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 7.01.516 Bariatric Surgery 10.01.514

More information

Infertility and Reproductive Services

Infertility and Reproductive Services BENEFIT COVERAGE GUIDELINE 4.02.503 Infertility and Reproductive Services Effective Date: Sept. 1, 2017 Last Revised: Aug. 22, 2017 Replaces: 4.02.04 RELATED GUIDELINES / POLICIES: None Select a hyperlink

More information

Panniculectomy and Excision of Redundant Skin

Panniculectomy and Excision of Redundant Skin MEDICAL POLICY 7.01.523 Panniculectomy and Excision of Redundant Skin Effective Date: March 1, 2018 Last Revised: Feb. 13, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 7.01.516 Bariatric Surgery 10.01.514

More information

Responsive Neurostimulation for the Treatment of Refractory Partial Epilepsy

Responsive Neurostimulation for the Treatment of Refractory Partial Epilepsy MEDICAL POLICY 7.01.143 Responsive Neurostimulation for the Treatment of Refractory Partial Epilepsy BCBSA Ref. Policy: 7.01.143 Effective Date: July 1, 2017 Last Revised: June 22, 2017 Replaces: N/A RELATED

More information

Reconstructive Breast Surgery/Management of Breast Implants

Reconstructive Breast Surgery/Management of Breast Implants BENEFIT COVERAGE GUIDELINE 7.01.533 Reconstructive Breast Surgery/Management of Breast Implants Effective Date: Nov 1, 2017 Last Revised: Oct. 19, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 7.01.503

More information

Surgical Treatments for Breast Cancer Related Lymphedema

Surgical Treatments for Breast Cancer Related Lymphedema MEDICAL POLICY 7.01.162 Surgical Treatments for Breast Cancer Related Lymphedema BCBSA Ref. Policy: 7.01.162 Effective Date: Jan. 4, 2019 Last Revised: Sept. 11, 2018 Replaces: N/A RELATED MEDICAL POLICIES:

More information

Pharmacologic Treatment of Idiopathic Pulmonary Fibrosis

Pharmacologic Treatment of Idiopathic Pulmonary Fibrosis PHARMACY POLICY 5.01.555 Pharmacologic Treatment of Idiopathic Pulmonary Fibrosis Effective Date: Feb. 1, 2018 Last Revised: Jan. 30, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.522 Treatment of

More information

Select a hyperlink below to be directed to that section. POLICY CRITERIA CODING RELATED INFORMATION EVIDENCE REVIEW REFERENCES HISTORY

Select a hyperlink below to be directed to that section. POLICY CRITERIA CODING RELATED INFORMATION EVIDENCE REVIEW REFERENCES HISTORY PHARMACY POLICY 5.01.529 Opioid Analgesics Effective Date: June 1, 2017 Last Revised: May 23, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.521 Pharmacologic Treatment of Neuropathy, Fibromyalgia and

More information

Surgery for Groin Pain in Athletes

Surgery for Groin Pain in Athletes MEDICAL POLICY 7.01.142 Surgery for Groin Pain in Athletes BCBSA Ref. Policy: 7.01.142 Effective Date: May 1, 2018 Last Revised: April 3, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink

More information

Electrical Bone Growth Stimulation of the Appendicular Skeleton

Electrical Bone Growth Stimulation of the Appendicular Skeleton MEDICAL POLICY 7.01.07 Electrical Bone Growth Stimulation of the Appendicular Skeleton BCBSA Ref. Policy: 7.01.07 Effective Date: July 1, 2017 Last Revised: June 6, 2017 Replaces: 7.01.529 RELATED MEDICAL

More information

Surgery for Groin Pain in Athletes

Surgery for Groin Pain in Athletes MEDICAL POLICY 7.01.142 Surgery for Groin Pain in Athletes BCBSA Ref. Policy: 7.01.142 Effective Date: May 1, 2018 Last Revised: April 3, 2018 Replaces: N/A RELATED MEDICAL POLICIES: None Select a hyperlink

More information

Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty)

Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty) MEDICAL POLICY 7.01.93 Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty) BCBSA Ref. Policy: 7.01.93 Effective Date: July 1, 2018

More information

Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures

Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures MEDICAL POLICY 7.01.85 Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures BCBSA Ref. Policy: 7.01.85 Effective Date: July 1, 2017 Last Revised: June 6, 2017 Replaces: 7.01.534

More information

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases MEDICAL POLICY 2.04.123 Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases BCBSA Ref. Policy: 2.04.123 Effective Date: Sept. 1, 2018 Last Revised: Aug.

More information

Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures

Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures MEDICAL POLICY 7.01.85 Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures BCBSA Ref. Policy: 7.01.85* Effective Date: July 1, 2018 Last Revised: June 22, 2018 Replaces: 7.01.534

More information

Ultrasound Accelerated Fracture Healing Device

Ultrasound Accelerated Fracture Healing Device MEDICAL POLICY 1.01.05 Ultrasound Accelerated Fracture Healing Device BCBSA Ref. Policy: 1.01.05 Effective Date: Dec. 21, 2017 Last Revised: Aug. 15, 2017 Replaces: N/A RELATED MEDICAL POLICIES: 2.01.40

More information